Latest Health News

Page 12 of 271
An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.
Ada Torres
Ada Torres
7 Oct 2026
Redox enters FY27 from a position of record revenue, higher margins and a debt-free balance sheet, while its North American business passes $100 million in sales. The chemical distributor also reported 9% higher average selling prices in the first quarter, although volumes remained broadly flat and freight costs increased.
Victor Sage
Victor Sage
7 Oct 2026
Vitasora says its remote-care model is now functioning, with estimated September-quarter revenue of US$1.028 million and a September exit rate of about US$17,400 a day. The next test is execution: turning planned Care Coordinator hiring into sustained, reconciled revenue and operational break-even.
Ada Torres
Ada Torres
6 Oct 2026
HealthCo Healthcare and Wellness REIT has signed binding agreements for new leases covering its remaining 10 Healthscope hospitals, subject to final approvals. The resolution allows HCW to reinstate quarterly distributions while reducing its largest tenant concentration from 57% to 31%.
Eva Park
Eva Park
5 Oct 2026
Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.
Victor Sage
Victor Sage
2 Oct 2026
Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.
Victor Sage
Victor Sage
2 Oct 2026
OMG Group has reported its first positive quarterly EBITDA, with preliminary Q1 FY27 net sales rising 59% to approximately $1.92 million. The result marks a potential inflection point for the health and wellness food company, although the figures remain unaudited and do not establish cash profitability.
Victor Sage
Victor Sage
1 Oct 2026
CONNEQT Health delivered sharp FY26 revenue growth and reduced its statutory loss as Pulse sales and clinical subscriptions expanded. But the ASX-listed medtech group ended the year with negative net assets, heavy cash burn and a material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.
Victor Sage
Victor Sage
30 Sept 2026
Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.
Victor Sage
Victor Sage
30 Sept 2026
Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.
Victor Sage
Victor Sage
30 Sept 2026
Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.
Ada Torres
Ada Torres
30 Sept 2026

Browse the archive

Full archive